Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

LncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma

A technology for auxiliary diagnosis, nasopharyngeal carcinoma, applied in the fields of molecular biology and oncology

Active Publication Date: 2016-09-14
THE FIRST PEOPLES HOSPITAL OF FOSHAN
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

LncRNA has been shown to be involved in the occurrence and development of many tumors, however, there are only a few reports on nasopharyngeal carcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma
  • LncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma
  • LncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] 1. Screening of lncRNA molecules related to nasopharyngeal carcinoma

[0050] 1. Case collection

[0051] A total of 19 patients who were hospitalized in the Nasopharyngeal Radiotherapy Department of the First People's Hospital of Foshan City, Guangdong Province from February 2014 to August 2014 were collected. All patients did not receive radiotherapy and chemotherapy before operation, other systemic medical history was excluded, and the functions of vital organs were within the normal range. They were aged 21-61 years, with a median age of 45 years. The clinical data of the samples are shown in Table 1. Six of them were randomly selected for treatment. Microarray study, and the remaining 13 cases were used for further verification. Informed consent of the patients was obtained for the collection of specimens in the experiment, and the authorization was obtained from the Ethics Committee of the First People's Hospital of Foshan City, Guangdong Province.

[0052] Tabl...

Embodiment 2

[0130] In order to further verify that lncRNA: ENST00000438553 can be used as a molecular marker or target of nasopharyngeal carcinoma, the inventor further expanded the number of samples and conducted further experiments.

[0131] 1. Case collection

[0132] From December 2012 to August 2015, the peripheral blood samples of nasopharyngeal cancer patients hospitalized in the Department of Head and Neck Radiotherapy, Foshan First People's Hospital were collected as the sample bank of the experimental group, while the non-cancer peripheral blood sample banks of the control group were collected from From September 2015 to November 2015, patients in the Health Care Department of Foshan First People's Hospital and inpatients in the Department of Otorhinolaryngology. The specimen collection in the trial obtained the informed consent of the patients and was authorized by the Ethics Committee of the First People's Hospital of Foshan City, Guangdong Province. All patients with nasophar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an lncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma. The nucleotide sequence of ENST00000438553 is shown as SEQ ID NO.1. The expression quantity of TCONS_00003617 in nasopharyngeal carcinoma tissues is significantly higher than that of pericarcinomatous tissues. The lncRNA molecule ENST00000438553 can be used as a nasopharyngeal carcinoma molecular marker or target in early clinical diagnosis, prognosis or targeted therapy of nasopharyngeal carcinoma, and is beneficial to further explication of the occurrence and development mechanism, signal pathway and the like of nasopharyngeal carcinoma, thus having remarkable application prospect and theoretical value.

Description

technical field [0001] The invention belongs to the fields of molecular biology and oncology, and specifically relates to an lncRNA molecule ENST00000438553 and its application in clinical diagnosis, treatment, prognosis evaluation or scientific research of nasopharyngeal carcinoma. Background technique [0002] Nasopharyngeal carcinoma (nasopharyngeal carcinoma, NPC) is one of the most common malignant tumors in southern China. It has the highest incidence rate in southern China, especially in Guangdong Province, ranking first in the world, so it is also called "Guangdong cancer". NPC is sensitive to radiation, and radiotherapy is the first choice, and its prognosis varies greatly depending on the stage of the disease. Radiotherapy alone is effective for stage I and stage II patients, and the 10-year disease-related survival rate, recurrence-free survival rate, and distant metastasis-free survival rate are all high. However, the onset of NPC is insidious, and the early sym...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12Q1/68
CPCC12N15/113C12N2310/10C12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 王跃建罗微夏世同唐隽陈伟雄
Owner THE FIRST PEOPLES HOSPITAL OF FOSHAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com